Blocking CXCR2 in early-stage disease may prevent the recruitment of anti-tumor neutrophils, but the effect of CXCR2 inhibition on TAN phenotypes necessitates further study and may vary depending upon the proportion of N1 versus N2 TANs in the TME. Here, CXCR2 is linked to neoplasm.